Currently approved therapies for infection by SARS-CoV-2, the etiological agent of the COVID-19 pandemic, include monoclonal antibodies and certain repurposed drugs such as dexamethasone. Monoclonal antibody therapy suffers from difficult logistics to administer, and the approved repurposed drugs have only modest effect on disease outcome. Some novel therapeutics developed for coronaviruses as well as further repurposed drugs 3 are under regulatory review as antivirals for SARS-CoV-2. Each has its own strengths but also drawbacks such as perceived concerns about mutagenicity, time to production ramp-up, or side-effect profile.